Abingdon Health plc
("Abingdon Health" or "the Company")
Director Share Transfer to Trust
York, U.K. 1 March 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), announces that it received notification on 28 February 2023 that Dr Chris Hand, Non-executive Chairman, transferred 3,000,000 ordinary shares of 0.025 pence each in the Company ("Ordinary Shares") from his personal account into The CW Hand 2023 Settlement, a discretionary trust in which Dr Hand is a trustee. Dr Hand retains an additional 10,027,667 Ordinary Shares outside of the trust.
Dr Hand has advised the Company that he has no intention of selling Ordinary Shares, either from those held inside the trust or those held outside of the trust.
Following this transaction the percentage of Ordinary Shares that Dr Hand retains outside of the trust combined with those for which he is a trustee remains at 10.7 per cent.
Further details are set out in the PDMR form below, made in accordance with the Market Abuse Regulation (EU) No. 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.
Enquiries
| Abingdon Health plc | ||
| Chris Yates, Chief Executive Officer | Via Walbrook PR | |
| Melanie Ross, Chief Financial Officer |
| |
| Chris Hand, Non-Executive Chairman |
| |
|
|
| |
| Singer Capital Markets (Sole Broker and Nominated Adviser) | Tel: +44 (0)20 7496 3000 | |
| Peter Steel, Alex Bond (Corporate Finance) |
| |
| Tom Salvesen (Corporate Broking) |
| |
| |
| |
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com | |
| Paul McManus / Phillip Marriage Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082 +44 (0)7407 804 654 | |
About Abingdon Health plc
Abingdon Health is a leading lateral flow contract development and manufacturing organisation ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success."
The Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes.
Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test ecommerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland such as pharmacy chains.
Founded in 2008, Abingdon Health is headquartered in York, England.
For more information visit: www.abingdonhealth.com
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
| a)
| Name
| Dr Chris Hand | ||||
| 2
| Reason for the notification | |||||
| a)
| Position/status | Non-executive Chairman | ||||
| b)
| Initial notification /Amendment | Initial Notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a)
| Name | Abingdon Health plc | ||||
| b)
| LEI
| 213800XFI4WV3FBILO20 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
| a)
| Description of the financial instrument, type of instrument | Ordinary Shares of 0.025 pence each | ||||
| | | |||||
| Identification code | GB00BLF79J41 | |||||
| | | |||||
| b)
| Nature of the transaction
| Transfer of 3,000,000 Ordinary Shares to The CW Hand 2023 Settlement Trust
| ||||
| c)
| Price(s) and volume(s) | | Price | Volume | | |
| | | N/A | 3,000,000 | | ||
| d)
| Aggregated information | | n/a single transaction | | | |
| | | |||||
| e)
| Date of the transaction | 28 February 2023 | ||||
| f)
| Place of the transaction | Off market
| ||||
| | | | | | | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.